TransCode Therapeutics RNAZ Stock
TransCode Therapeutics Price Chart
TransCode Therapeutics RNAZ Financial and Trading Overview
| TransCode Therapeutics stock price | 0.44 USD |
| Previous Close | 2.77 USD |
| Open | 2.76 USD |
| Bid | 2.6 USD x 900 |
| Ask | 2.68 USD x 1400 |
| Day's Range | 2.62 - 2.8 USD |
| 52 Week Range | 2.48 - 31.6 USD |
| Volume | 135.16K USD |
| Avg. Volume | 181.03K USD |
| Market Cap | 7.11M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -47.14 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 120 USD |
RNAZ Valuation Measures
| Enterprise Value | 1.49M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.3292403 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.075 |
Trading Information
TransCode Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -89.041% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 31.6 USD |
| 52 Week Low | 2.48 USD |
| 50-Day Moving Average | 5.78 USD |
| 200-Day Moving Average | 11.76 USD |
RNAZ Share Statistics
| Avg. Volume (3 month) | 181.03K USD |
| Avg. Daily Volume (10-Days) | 907.36K USD |
| Shares Outstanding | 2.7M |
| Float | 527.63K |
| Short Ratio | 0.95 |
| % Held by Insiders | N/A |
| % Held by Institutions | N/A |
| Shares Short | 27.12K |
| Short % of Float | 4.26% |
| Short % of Shares Outstanding | 3.18% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -102.74% |
| Return on Equity (ttm) | -225.62% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -19982780 USD |
| Net Income Avi to Common (ttm) | -18911832 USD |
| Diluted EPS (ttm) | -30.51 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.63M USD |
| Total Cash Per Share (mrq) | 1.92 USD |
| Total Debt (mrq) | 768.23K USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.798 |
| Book Value Per Share (mrq) | -0.299 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -16327497 USD |
| Levered Free Cash Flow (ttm) | -9700337 USD |
Profile of TransCode Therapeutics
| Country | United States |
| State | MA |
| City | Boston |
| Address | 6 Liberty Square |
| ZIP | 02109 |
| Phone | 857-837-3099 |
| Website | https://www.transcodetherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 19 |
TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.
Q&A For TransCode Therapeutics Stock
What is a current RNAZ stock price?
TransCode Therapeutics RNAZ stock price today per share is 0.44 USD.
How to purchase TransCode Therapeutics stock?
You can buy RNAZ shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for TransCode Therapeutics?
The stock symbol or ticker of TransCode Therapeutics is RNAZ.
Which industry does the TransCode Therapeutics company belong to?
The TransCode Therapeutics industry is Biotechnology.
How many shares does TransCode Therapeutics have in circulation?
The max supply of TransCode Therapeutics shares is 23.34M.
What is TransCode Therapeutics Price to Earnings Ratio (PE Ratio)?
TransCode Therapeutics PE Ratio is now.
What was TransCode Therapeutics earnings per share over the trailing 12 months (TTM)?
TransCode Therapeutics EPS is -47.14 USD over the trailing 12 months.
Which sector does the TransCode Therapeutics company belong to?
The TransCode Therapeutics sector is Healthcare.
TransCode Therapeutics RNAZ included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17376.52 USD — |
+0.06
|
9.4B USD — | 17256.2 USD — | 17425.17 USD — | — - | 9.4B USD — |
| NASDAQ HealthCare IXHC | 937.2 USD — |
+0.66
|
— — | 922.07 USD — | 938.35 USD — | — - | — — |
- {{ link.label }} {{link}}